Pharmatest collaborates with Envigo in preclinical studies
Pharmatest has started a successful collaboration in preclinical studies with one of the world’s leading CROs. The collaboration with Envigo includes the provision of specialised bone safety assessment to support regulatory preclinical studies for novel therapies.
Pharmatest Services Ltd (Pharmatest) is a contract research organization that offers preclinical efficacy services for the pharmaceutical industry in the fields of oncology and skeletal diseases. Envigo provides essential products and research services for pharmaceutical, crop protection, chemical companies and research organizations.
The collaboration between Pharmatest and Envigo started in 2015 when Envigo required specialist support on a pivotal GLP investigation to address a specific regulatory question relating to bone safety assessment for a European Sponsor. As part of the study, Envigo representatives visited Pharmatest on several occasions to assess capabilities, monitor procedures and audit the data and contributory report in order for the Envigo study director to claim GLP compliance for this phase of the study.
Senior Pharmaceutical Programme Manager of Envigo says: “Initial discussions with Pharmatest suggested that they would be the best facility for this very specialized work and the service we received was of the highest quality. Working closely together, Envigo and Pharmatest have met the challenging requirements set by the Sponsor.”
Jussi Halleen, Chief Executive Officer of Pharmatest comments: “So far the collaboration with Envigo has been an excellent learning process for Pharmatest and improved our general procedures and understanding of the requirements for a GLP study. We look forward to continuing the fruitful collaboration with Envigo in future studies.”